Daiichi Sankyo signs agreement with AstraZeneca to co-commercialise MOVANTIK in the US
20 March 2015 | By Victoria White
Daiichi Sankyo has announced a co-commercialisation agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US with plans to launch in April 2015..